NEOPLASMA

Scope & Guideline

Transforming Cancer Research into Clinical Practice

Introduction

Welcome to your portal for understanding NEOPLASMA, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0028-2685
PublisherAEPRESS SRO
Support Open AccessNo
CountrySlovakia
TypeJournal
Convergefrom 1957 to 2024
AbbreviationNEOPLASMA / Neoplasma
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressBAJZOVA 7, BRATISLAVA 821 08, SLOVAKIA

Aims and Scopes

NEOPLASMA is a peer-reviewed journal that focuses on various aspects of cancer research, including molecular mechanisms, clinical studies, and innovative therapeutic strategies. The journal aims to provide a platform for researchers to share their findings and insights on the complexities of cancer biology and treatment.
  1. Molecular Mechanisms of Cancer:
    Research focusing on the underlying biological processes and molecular pathways that contribute to cancer development and progression, including studies on gene expressions, signaling pathways, and cellular interactions.
  2. Therapeutic Strategies and Clinical Trials:
    Papers that explore novel treatments, drug combinations, and clinical trial results aimed at improving patient outcomes in various cancer types.
  3. Cancer Biomarkers and Diagnostics:
    Studies aimed at identifying and validating biomarkers for cancer diagnosis, prognosis, and treatment response, facilitating personalized medicine approaches.
  4. Tumor Microenvironment and Metastasis:
    Research that investigates the interactions between tumor cells and their microenvironment, including the role of stromal cells, immune responses, and metastatic behavior.
  5. Preclinical and Translational Research:
    Emphasis on the development of innovative models and methodologies to study cancer, including in vitro and in vivo studies that bridge laboratory findings to clinical applications.
In recent years, NEOPLASMA has seen a notable increase in the publication of research focused on innovative and interdisciplinary approaches to cancer treatment and understanding. These emerging themes reflect the evolving landscape of cancer research.
  1. Targeted and Personalized Therapies:
    An increasing number of studies are focusing on targeted therapies, particularly those tailored to specific genetic mutations and biomarkers, indicating a shift towards precision medicine in oncology.
  2. Immunotherapy and Immune Checkpoint Inhibitors:
    Research examining the mechanisms and efficacy of immunotherapies, particularly immune checkpoint inhibitors, is on the rise as these treatments become central to cancer management.
  3. Ferroptosis and Novel Cell Death Mechanisms:
    Emerging interest in ferroptosis and other forms of regulated cell death as potential therapeutic targets reflects a deeper understanding of cancer biology and treatment resistance.
  4. MicroRNA and Long Non-Coding RNA Research:
    Studies exploring the roles of microRNAs and long non-coding RNAs in cancer progression and therapy resistance are increasingly prevalent, highlighting the importance of non-coding RNA in tumor biology.
  5. Cancer Metabolism and Metabolic Reprogramming:
    Research focusing on the metabolic adaptations of cancer cells and how these can be targeted for therapeutic benefit is gaining traction, reflecting a broader interest in cancer cell biology.

Declining or Waning

While NEOPLASMA continues to be a leading journal in cancer research, certain themes have shown a decline in publication frequency, reflecting shifts in research priorities and emerging interests in the field.
  1. Traditional Chemotherapy Studies:
    Research focused solely on traditional chemotherapy regimens is less frequent, as there is a growing emphasis on targeted therapies and immunotherapy approaches.
  2. Basic Histopathological Studies:
    Papers that primarily describe histopathological features without integrating molecular or genetic analyses are becoming less prominent, reflecting a shift towards more comprehensive approaches that combine multiple disciplines.
  3. Single-Agent Drug Studies:
    There is a noticeable decline in studies investigating the efficacy of single-agent therapies, as combination therapies and multi-modal treatment strategies are gaining more attention.
  4. Non-Clinical Research:
    Research that lacks translational relevance or direct clinical implications is decreasing, as the focus shifts towards studies that can directly inform clinical practice and patient care.

Similar Journals

Journal of Cancer Metastasis and Treatment

Unraveling the complexities of cancer treatment.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

BIOLOGICAL PROCEDURES ONLINE

Catalyzing Discoveries in Biochemistry and Molecular Science.
Publisher: BMCISSN: Frequency: 1 issue/year

BIOLOGICAL PROCEDURES ONLINE is a premier open-access journal published by BMC, dedicated to advancing the fields of biochemistry, genetics, and molecular biology. With its electronic ISSN 1480-9222 and a strong commitment to accessibility since 2009, this journal provides a vital platform for researchers and scholars to disseminate their findings and foster collaboration within the scientific community. Based in the United Kingdom, this journal has garnered an impressive reputation, achieving Q1 status in the 2023 category rankings, with notable inclusion in the Scopus rankings, placing it in the 86th percentile among 221 peer journals in the general biochemistry, genetics, and molecular biology domain. It covers a broad range of topics, ensuring coverage of the latest advancements and methodologies in biological procedures, making it an essential resource for academics, practitioners, and students alike. Researchers are encouraged to submit their innovative work and contribute to the ongoing dialogue in this dynamic and ever-evolving field.

CANCER AND METASTASIS REVIEWS

Illuminating Pathways in Oncology and Metastasis
Publisher: SPRINGERISSN: 0167-7659Frequency: 4 issues/year

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Molecular & Cellular Oncology

Connecting researchers to the forefront of oncology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

ONCOLOGY RESEARCH

Fostering Excellence in Oncology Research and Practice
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

MOLECULAR CANCER THERAPEUTICS

Connecting science and healing in the fight against cancer.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

BRITISH JOURNAL OF CANCER

Shaping the Future of Oncology Through Quality Scholarship.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Cancer Communications

Unlocking Insights in Oncology for All
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Molecular and Clinical Oncology

Transforming insights into impactful oncology practices.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

CANCER SCIENCE

Pioneering discoveries in cancer biochemistry and genetics.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.